Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
DOD Biotech Public Co., Ltd. (DOD.BK)
Mueang Samut Sakhon, TH
DOD Biotech Public Company Limited, together with its subsidiaries, manufactures and distributes dietary supplements in Thailand. It offers dietary supplements for beauty and health in various forms comprising capsules, gels, jellies, powder, shot drinks, soft gels, tablets, probiotics, gummies, and direct-to-mouth. The company also provides food supplements and health drinks. In addition, it offers advisory, trading, and supplementary services; and research and development, design, FDA and HALAL registration, and consulting services. DOD Biotech Public Company Limited was incorporated in 2011 and is based in Mueang Samut Sakhon, Thailand.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.20% | -2.38% | +0.00% | -18.81% | +0.61% | +1.23% | +2.50% | -61.14% | -87.38% | -88.84% | -88.84% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%-5.6% Q1'26: -29.9% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+137.1% ★ Q1'26: -180.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+9.8% Q1'26: -66.2% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+4.5% Q1'26: -12.6% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+3.7% Q1'26: -6.4% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×1.00× ★ Q1'26: -4.21× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
|---|---|---|---|---|
| Revenue |
666.36M
est: 735.00M (-9.3%)
|
789.92M
est: 633.00M (+24.8%)
|
1.61B
est: 1.36B (+18.7%)
|
1.02B
est: 1.52B (-33.2%)
|
| EBITDA |
333.01M
est: 41.99M (+693.1%)
|
142.26M
est: 36.16M (+293.4%)
|
408.07M
est: 77.52M (+426.4%)
|
338.82M
est: 86.83M (+290.2%)
|
| EBIT |
308.51M
est: -22.10M (+1,496.0%)
|
86.22M
est: -19.03M (+553.0%)
|
331.50M
est: -40.80M (+912.5%)
|
271.78M
est: -45.70M (+694.7%)
|
| Net Income |
305.26M
est: 334.54M (-8.8%)
|
86.71M
est: 402.11M (-78.4%)
|
141.25M
est: 211.19M (-33.1%)
|
233.10M
est: 359.47M (-35.2%)
|
| SGA |
105.26M
est: 193.15M (-45.5%)
|
329.69M
est: 166.34M (+98.2%)
|
433.21M
est: 356.60M (+21.5%)
|
126.84M
est: 399.43M (-68.2%)
|
| EPS |
0.85
est: 0.74 (+14.4%)
|
0.21
est: 0.89 (-76.5%)
|
0.34
est: 0.47 (-27.5%)
|
0.57
est: 0.80 (-28.6%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-28 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-27 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-26 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-25 | B- | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-22 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-21 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-20 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-19 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-18 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-15 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-14 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-13 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 1/5 | 3/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-07 | A- | 4/5 | 1/5 | 3/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-06 | A- | 4/5 | 1/5 | 3/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-05 | A- | 4/5 | 1/5 | 3/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-29 | B+ | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 2/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 2/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 2/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 2/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 2/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 2/5 | 5/5 | 2/5 | 4/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Torlarp Chaiyachow | CEO & Director | 60.0K | male |
| Suwarin Konthong | Chief Financial Officer & Executive Director | 60.0K | female |
| Nattawat Phetthai | Chief Accountant, Accounting & Finance Manager | — | male |
| Arachaporn Boonnkerd | Company Secretary | — | female |
| Watcharaporn Klabwongsa | COO & Chief Administration Officer | — | female |
| Supaporn Kaewyai | Account Controller | — | female |
| Darunee Kongphakdee | Chief Marketing Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DOD.BK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
